
A new contrast-based Doppler ultrasound technique can predict within the first two weeks of treatment which patients with gastrointestinal stromal tumors (GIST) will respond to Gleevec (imatinib) therapy, according to a study presented at the 2005 American Society of Clinical Oncology meeting in Orlando.

























